Skip to main content
. 2014 Mar 14;3(4):465–473. doi: 10.1016/j.molmet.2014.02.005

Figure 2.

Figure 2

FABP4 potentiates glucose-stimulated insulin secretion in vitro and in vivo. A, B, Isolated mouse islets were exposed to recombinant FABP4 (rFABP4) for 24 h, with or without the fatty acids palmitate or linoleate, before 20 mM GSIS was assessed for 1 h (A), and islet insulin content assayed after lysis (B); n = 3–4. C–F, Osmotic mini-pumps containing rFABP4–linoleate (1:1) or saline were implanted (subcutaneously) in mice for 7 days providing continuous rFABP4 infusion (1.22 μg/h), before glucose tolerance (C), insulin secretion (D) and body mass (F) were assessed; n = 15 mice. To account for day-to-day variation in insulin assay results, mean insulin levels 30 min post-glucose from each experimental day were presented as paired treatment groups (n = 3) (E). G, Intraperitoneal co-injection of an rFABP4 bolus (80 μg), or PBS control, along with glucose (2 g/kg) revealed that acute administration of FABP4 does not alter glucose tolerance; n = 5 mice. Data presented as mean ± SEM. *P < 0.05 by unpaired (A) or paired (E) t-test. P < 0.01 by 2-way ANOVA for treatment effect indicated in C. See also Figure S1.